Imperial College London
Alternate

Dr Alex Digesu

Faculty of Medicine, Department of Metabolism, Digestion and Reproduction

Honorary Clinical Senior Lecturer
 
 
 
//

Contact

 

+44 (0)20 3312 1752a.digesu CV

 
 
//

Location

 

Urogynaecology DepartmentCambridge WingSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Bhide:2019:10.1007/s00192-018-3844-7,
author = {Bhide, AA and Khullar, V and Swift, S and Digesu, GA},
doi = {10.1007/s00192-018-3844-7},
journal = {International Urogynecology Journal and Pelvic Floor Dysfunction},
pages = {683--692},
title = {The use of laser in urogynaecology},
url = {http://dx.doi.org/10.1007/s00192-018-3844-7},
volume = {30},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - IntroductionThe use of lasers in urogynaecology has increased in recent years. Their use has been described in pelvic organ prolapse, urinary incontinence and genito-urinary symptoms of menopause. The aim of this study was to review the published literature on CO2 and erbium:YAG laser use in urogynaecological conditions.MethodsAn extensive search of literature databases (PubMed, EMBASE) was performed for publications (full text and abstracts) written in English up to July 2018. Relevant trials were selected and analysed by an independent reviewer. Twenty-five studies were identified in total.ResultsAll studies were either prospective cohort or case-control studies. The results of individual studies indicate that both CO2 and erbium lasers are effective in treating urogynaecological conditions. Most studies use a vaginal approach with only two investigations of intraurethral application.ConclusionThe use of lasers to treat these conditions may seem appealing; however, the lack of good-quality evidence in the form of multi-centre randomised placebo-controlled trials is concerning. The safety and effectiveness of these laser devices have not been established. Use of lasers may lead to serious adverse events such as vaginal burns, scarring, dyspareunia and chronic pain. Randomised placebo-controlled trials in addition to formal evaluation of the laser devices are required before this treatment modality can be recommended.
AU  - Bhide,AA
AU  - Khullar,V
AU  - Swift,S
AU  - Digesu,GA
DO  - 10.1007/s00192-018-3844-7
EP  - 692
PY  - 2019///
SN  - 0937-3462
SP  - 683
TI  - The use of laser in urogynaecology
T2  - International Urogynecology Journal and Pelvic Floor Dysfunction
UR  - http://dx.doi.org/10.1007/s00192-018-3844-7
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000466445100003&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://link.springer.com/article/10.1007%2Fs00192-018-3844-7
UR  - http://hdl.handle.net/10044/1/74250
VL  - 30
ER  -
Download